Bavarian Nordic AS
BV3
Company Profile
Business description
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
Contact
Philip Heymans Alle 3
Hellerup2900
DNKT: +45 33268383
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,861
Stocks News & Analysis
stocks
Two cheap wide moat ASX shares
These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.
stocks
Anthropic: Are the shares undervalued given the IPO pricing range?
There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.
stocks
Valuation looks stretched for ASX healthcare share
Strong fundamentals meet a demanding valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,274.20 | 17.10 | -0.18% |
| CAC 40 | 8,384.71 | 51.84 | 0.62% |
| DAX 40 | 26,835.27 | 172.50 | 0.65% |
| Dow JONES (US) | 52,486.49 | 254.60 | 0.49% |
| FTSE 100 | 10,860.56 | 25.09 | 0.23% |
| HKSE | 24,008.55 | 307.37 | -1.26% |
| NASDAQ | 25,466.19 | 400.32 | 1.60% |
| Nikkei 225 | 60,819.36 | 429.23 | -0.70% |
| NZX 50 Index | 14,259.23 | 79.37 | 0.56% |
| S&P 500 | 7,619.38 | 98.45 | 1.31% |
| S&P/ASX 200 | 9,146.80 | 6.40 | -0.07% |
| SSE Composite Index | 3,655.83 | 24.81 | -0.67% |